Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis

Table 2 Impacts of 24 weeks therapies of DMARDs on urinary PGIM, TXBM, 12-HETE and LTE₄

	PGIM			TXBM			12-HETE			LTE₄
	Day 0	Week 24	P^a	Day 0	Week 24	P^a	Day 0	Week 24	P^b	Day 0	Week 24	P^b
Total	25.66%	40.79%	0.069	43.42%	69.74%	0.056	67.53.%	72.73%	0.419	23.38%	28.57%	0.669
ACT	28.95%	50.00%	0.172	65.79%	76.32%	0.723	63.16%	78.95%	0.098	23.68%	26.32%	0.904
CZP	19.05%	30.95%	0.320	16.67%	61.90%	< 0.001	Not measured
ABA	38.46%	51.28%	0.194	66.67%	82.05%	0.131	71.79%	66.67%	0.653	23.08%	30.77%	0.588
TCZ	15.15%	30.30%	0.218	24.24%	57.58%	0.019	Not measured

ACT, Active Conventional Therapy arm; CZP, Certolizumab Pegol arm; ABA, Abatacept arm; TCZ, Tocilizumab arm; PGIM, 2,3-dinor-6-keto-PGF_1α; TXBM, 2,3-dinor-TXB₂, 12-HETE, 12-Hydroxyeicosatetraenoic Acid; LTE₄, Leukotriene E₄; GEE, Generalized Estimating Equations
P values were obtained from the following statistical tests:
^aGEE model adjusted for use of NSAIDs and creatinine concentrations
^bGEE model adjusted for creatinine concentrations

ISSN: 1478-6362